Australia, a Hotbed for Regenerative Medicine

Wednesday, 7 June 2017
AGC Asahi Glass has entered into a strategic collaboration and license agreement with Regeneus. Regeneus is developing an allogeneic adipose-derived MSC therapy called Progenza for the treatment of osteoarthritis (OA) and has recently concluded a Phase I trial in Australia.